The global Diabetic Macular Edema Treatment Market is projected to grow at a CAGR of 3.5% during the forecast period 2021 to 2027. Diabetic macular edema is a leading cause of vision impairment among people. Macular edema occurs when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling leading to distorted vision. Diabetic macular edema is a disease that is followed by diabetic retinopathy. Diabetic retinopathy is the condition which severely damages the blood vessels of the retina, resulting in vision defects or vision loss. These blood vessels, if left untreated, due to pressure in the eye results in fluid leakage, causing Diabetic Macular Edema (DME). Increase in the prevalence of diabetes is the major factor driving growth of global market. The prevalence of diabetic macular edema is found to be higher in type 2 diabetes patients than in type 1 diabetes patients. In the projected period of 2020-2027, new and creative research and development for the treatment of diabetic macular edoema would likely increase the growth of the diabetic macular edema treatment market. On the other hand, advancements in ophthalmic surgery techniques and pharmaceutical firms’ R&D investments would enhance numerous opportunities, resulting in the diabetic macular edoema treatment market growing over the projection period. During the projected period, the diabetic macular edoema treatment market is expected to be hampered by high medical costs for patients and frequent visits to physicians. There is no need for treatment in the early stages of DME unless the patients are able to keep their blood sugar levels under control. Laser photocoagulation is the standard treatment for diabetic macular edoema if the condition becomes severe. This method involves administering a pattern of burns or cauterising leaky blood vessels using a laser to minimise edoema. Retinal experts use anti-vascular endothelial growth factorcorticosteroids injections in combination with laser photocoagulation to avoid the treatment’s negative effects. Only two approved medications for treating DME are now available on the market: Lucentis and Ozurdex. Clinical trials are now underway for other therapy options.